Rifaximin in the treatment of hepatic encephalopathy
Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli, Carmelina LoguercioDepartment of Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Hepatogastroenterology Unit, Second University of Naples, Naples, ItalyAbstract: Hepatic encephalopathy is a challenging...
Saved in:
Main Authors: | Iadevaia MD, Del Prete A, Cesaro C, Gaeta L, Zulli C, Loguercio C |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/7e2e851629b54db6874a1d0ff5ab8e86 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
by: Roggeri DP, et al.
Published: (2017) -
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
by: Roggeri DP, et al.
Published: (2015) -
Epidemiology and treatment of autoimmune hepatitis
by: Francque S, et al.
Published: (2012) -
Hepatitis C in Argentina: epidemiology and treatment
by: Gaite LA, et al.
Published: (2014) -
Interferon-free combination therapies for the treatment of hepatitis C: current insights
by: Holmes JA, et al.
Published: (2015)